Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 84

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 84
---
 to APx under the Bioceres Notes. As of March31, 2025, $1,500,000 has been drawn under the SOFOM Loan. Amounts outstanding under the SOFOM Loan will mature upon the earlier to occur of February26, 2026 or the date that is 30 days after the termination of the Lock -UpPeriod (as defined in the Registration Rights and Lock -UpAgreement). If APx does not complete an initial business combination, it is unlikely that Bioceres will recover funds drawn by APx under the BC Promissory Notes, which may be used to repay the SOFOM Loan. Conversely, if the Business Combination closes, APx will repay the BC Promissory Notes to Bioceres, which funds may be used repay the SOFOM Loan; •pursuant to the EarlyBird Engagement Letter, if the Business Combination closes, EarlyBird is entitled to the EarlyBird Fees, which consist of $2,000,000, up to $500,000 of which may be paid in Company Shares on the six -monthanniversary of the Closing. If the Closing does not occur, EarlyBird will not be entitled to the EarlyBird Fees; 8 •the Sponsor is expected to hold an aggregate of approximately 9.5%, and the Initial Sponsor is expected to hold an aggregate of approximately 2.8%, of the outstanding Company Shares upon the consummation of the Business Combination, assuming no redemptions by Public Shareholders; •although there are no such unreimbursed out -of -pocketexpenses as of June30, 2024, unless a business combination is consummated, members of the APx Board will not receive reimbursement for any out -of -pocketexpenses incurred by them on APx’s behalf incident to identifying, investigating, negotiating and completing a business combination to the extent such expenses exceed the amount not required to be retained in the Trust Account; •the continuation of Kyle Bransfield, the chairman of the APx Board, as a director of the Company, and his appointment as chief financial officer of the Company, following the Closing; •the continued indemnification of APx’s current and former officers and directors and the continuation of directors’ and officers’ liability insurance after the Business Combination; •APx’s Existing Governing Documents provide that APx renounces its interest in any corporate opportunity offered to any director or officer unless such opportunity is expressly offered to such person solely in his or her capacity